

VRL/SEC/EXCHANGE

26.10.2026

National Stock Exchange of India Ltd. 5 th Floor, Exchange Plaza Bandra (E), Mumbai- 400051 Script Code: VENUSREM	BSE Limited 25 th Floor, Phiroze Jeejeebhoy Towers Dalal Street Mumbai-400051 Script Code: 526953
--	--

Sub.: Outcome of Board Meeting date 26th October 2026 and Unaudited Financial Results for the period ended on 30th September 2026.

Dear Sir/ Madam,

This has reference to the meeting of Board of Directors held on 26th October 2026 inter alia considered and approved Unaudited Financial Results (Standalone and Consolidated) for the period ended on 30th September 2026 along with Limited Review report.

Unaudited Financial Results for the period ended on 30th September 2026 along with the Limited Review report are enclosed herewith.

Meeting commenced at 02:45 pm and concluded at 06:00 pm.

Kindly take the above information on your record.

Thanking you.

**Yours faithfully,
for VENUS REMEDIES LIMITED**

Neha
Neha
(Company Secretary)
M.No. 8374

Digitally signed by Neha
Date: 2026.10.26 18:27:52 +05'30'

VENUS REMEDIES LIMITED

CIN : L21002CH1989PLC009705

Corporate Office :

51-52, Industrial Area, Phase- I, Panchkula (Hry.)
134113, India

Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.vmrindia.com
email : info@venusremedies.com

Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-2933090, 2933094, Fax : +91-172-2565566

Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel.: +91-1792-242100, 242101

Unit-V :

VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368,
Werne, Germany





J. K. JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

S.C.O. 1136-37, SECTOR 22-B, CHANDIGARH - 160 022

0172-270 4536-37 Fax : 0172-270 4537

E - mail : jkjcaps@rediffmail.com

Independent Auditor's Limited Review Report on Quarterly Unaudited Standalone Financial Results of Venus Remedies Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

The Board of Directors

VENUS REMEDIES LIMITED

1. We have reviewed accompanying statement of unaudited standalone financial results of **VENUS REMEDIES LIMITED** ("the Company"), for the Quarter and half year ended 30th September 2026 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement which is responsibility of company's Management has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. The Statement has been approved by the Company's Board of Directors. Our responsibility is to report a conclusion on these statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.



5. Emphasis of matter:

1. We draw attention to Note 5 of the accompanying Statement, which describes the outstanding share application money amounting to INR 2,859.72 Lakhs in respect of *Venus Pharma GmbH*, a wholly owned subsidiary of the Company. The share allotment against this amount has been pending and as per management representation it is not mandatory to allot under the applicable laws of Germany

Management has represented that they consider this investment strategic in nature and that the parent company intends to recover this amount in due course as a result of the restructuring of European operations carried out by the Management in FY 2026-27. Although the subsidiary is currently facing financial challenges, the Company has reiterated its intention to provide the necessary financial and operational support during the transition period.

Our conclusion is not modified in respect of these matters.

For J.K Jain & Associates
Chartered Accountants
FRN-004025N



CA Anurag Verma
Partner
M. No. 555033
UDIN: 26555033EUGZTF3448
Date: 26th October, 2026

CIN : L21002CH1989PLC009705

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON
30TH SEPTEMBER 2026**

(Rs. In Crores except EPS)

S. No.	PARTICULARS	QUARTER ENDED ON			HALF YEAR ENDED ON		YEAR ENDED ON
		30/09/2026	30/06/2026	30/09/2025	30/09/2026	30/09/2025	31/03/2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue						
	(a) Revenue from Operations	218.76	178.80	192.65	397.55	329.78	768.73
	(b) Other Income	0.40	2.55	1.68	2.95	4.40	11.45
	Total Income	219.16	181.35	194.33	400.50	334.18	780.19
2	Expenses						
	(a) Cost of Material Consumed	97.39	83.14	106.51	180.53	177.84	387.95
	(b) Purchase of stock in trade	2.13	1.12	1.87	3.26	4.13	10.76
	(c) Changes in Inventories of finished goods, work-in-progress & Stock in Trade	6.73	0.02	(1.06)	6.75	(0.51)	(11.47)
	(d) Employee benefits expense	25.82	22.56	22.03	48.38	41.29	84.85
	(e) Depreciation & amortization expense	9.27	6.51	5.92	15.78	11.87	24.69
	(f) Selling ,Manufacturing and Administrative expenses	35.43	31.17	28.43	66.60	50.81	134.28
	(g) Research & Development expenses	5.62	4.23	5.03	9.85	8.44	18.44
	Total Expense	182.39	148.75	168.73	331.15	293.87	649.51
3	Profit before taxes (1-2)	36.77	32.61	25.60	69.35	40.31	130.67
4	Exceptional Items	-	-	-	-	-	-
5	Profit after exceptional items (3 + 4)	36.77	32.61	25.60	69.35	40.31	130.67
	EBIDTA (3+2e)	46.04	39.12	31.52	85.13	52.18	155.37
6	Tax Expenses						
A	Current Tax	9.25	8.20	6.45	17.46	10.15	32.89
B	Deferred Tax	(1.44)	(1.13)	(0.09)	(2.57)	(0.79)	(1.52)
C	Tax expense related to previous year	-	-	-	-	-	-
5	Profit before tax (3 +/- 4)	28.96	25.53	19.24	54.46	30.95	99.31
6	Income Tax Expense /Deferred Tax(Benefits)	-	-	-	-	-	-
7	Net Profit /(Loss) for the period (5 - 6)	28.96	25.53	19.24	54.46	30.95	99.31
8	Other Comprehensive Income						
A	(I) Items that will not be reclassified to Profit & loss	0.03	0.03	(0.12)	0.06	(0.24)	0.11
B	(I) Items that may be reclassified to Profit & loss (II) Income tax relating to items that may be reclassified to Profit & loss	(0.46)	5.89	0.63	5.43	4.36	0.71
C	Total other comprehensive Income Net of Income Tax	(0.43)	5.92	0.51	5.49	4.12	0.83
9	Total comprehensive Income for the period (7+/-8)	28.53	31.45	19.75	59.95	35.07	100.14
10	Paid up equity share capital (Face Value of Equity Shares)	13.37 10	13.37 10	13.37 10	13.37 10	13.37 10	13.37 10
11	Other Equity	-	-	-	-	-	676.26
12	Earning per share (of Rs. 10/- each)						
	(a) Basic (₹)	21.66	19.10	14.40	40.74	23.15	74.29
	(b) Diluted (₹)	21.66	19.10	14.40	40.74	23.15	74.29




For VENUS REMEDIES LIMITED
[Signature]
CHAIRMAN & MANAGING DIRECTOR

CIN : L21002CH1989PLC009705

Unaudited Statement of Standalone Assets and Liabilities

Particulars	(₹ In Crore)	
	As at 30/09/2026 (Un Audited)	As at 31/03/2026 (Audited)
ASSETS		
Non-Current Assets		
(a) Property, Plant & Equipment	105.80	110.23
(b) Capital Work in Progress	74.76	51.36
(c) Intangible Assets	83.92	92.20
(d) Right of use Assets	11.24	12.19
(e) Financial Assets		
(i) Investments	172.50	163.95
(ii) Other Financial Assets	35.02	36.34
(f) Other Non-Current Assets	5.71	3.99
Total Non Current Assets	488.95	470.26
Current Assets		
(a) Inventories	132.14	129.37
(b) Financial Assets		
(i) Investment	68.08	73.80
(ii) Trade Receivables	105.85	116.39
(iii) Cash and Cash Equivalents	17.57	23.54
(iv) Others Bank Balances	3.93	4.49
(v) Other Financial Assets	0.38	0.36
(c) Current Tax Assets	8.23	8.18
(d) Other Current Assets	42.91	49.68
Total Current Assets	379.09	405.80
Total Assets	868.04	876.06
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	13.37	13.37
(b) Other Equity	722.85	676.26
Total equity	736.22	689.63
Liabilities		
Non-Current Liabilities		
(a) Provisions	3.53	2.81
(b) Deferred Tax Liabilities (Net)	11.65	14.34
(c) Financial Liabilities		
(i) Lease Liabilities	10.32	11.05
Total Non-Current Liabilities	25.50	28.20
Current Liabilities		
(a) Financial Liabilities		
(i) Trade Payables		
(a) Total outstanding dues of micro enterprises and small enterprises	13.69	12.41
(b) Total outstanding dues of creditors other than micro and small enterprises	36.52	98.36
(ii) Lease Liabilities	1.42	1.36
(iii) Other Financial Liabilities	50.32	39.82
(b) Other Current Liabilities	2.08	1.96
(c) Provisions	2.29	4.32
Total Current Liabilities	106.32	158.24
Total Equity and Liabilities	868.04	876.06




For VENUS REMEDIES LIMITED
[Signature]
CHAIRMAN & MANAGING DIRECTOR

CIN : L21002CH1989PLC009705

UNAUDITED STATEMENT OF STANDALONE CASH FLOW FOR THE PERIOD ENDED 30TH SEPTEMBER 2026

		(₹ in Crore)	
	PARTICULARS	For the Year Ended 30/09/2026 Un Audited	For the Year Ended 30/09/2025 Un Audited
A)	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit Before Tax	69.35	40.31
	Adjustment for Depreciation	15.78	11.87
	Adjustment for loss/(profit) on sale of Property plant and Equipment	0.01	0.07
	Interest Expense	0.52	-
	Rent Received	(0.23)	(0.21)
	Gain on sale of Mutual Funds	(1.79)	(1.55)
	Interest Received	(0.37)	(1.22)
	Operating Profit before working capital changes	83.27	49.27
	Less: Tax Paid	(22.02)	(9.22)
	Adjustments for increase /decrease in Current Assets	15.03	13.55
	Decrease / Increase in Current Liabilities/ Provisions	(49.93)	33.61
	Decrease / Increase in Others Non-Current Assets and Other Financial Assets	(0.41)	(2.73)
	Provision for gratuity, leave encashment and Income tax	1.37	(4.70)
	Net Cash Flow from operating activities (A)	27.30	79.78
B)	CASH FLOW FROM INVESTING ACTIVITIES		
	Rent Received	0.23	0.21
	Purchase of Property plant and equipment	(25.86)	(12.90)
	Right of Use Assets	-	(0.05)
	Sale of Property plant and equipment	0.33	0.06
	Investment in Mutual Funds / Fixed Deposit	4.42	(103.71)
	Gain on sale of Mutual Funds	1.79	1.55
	Interest Received	0.37	1.22
	Net Cash Flow from Investing Activities (B)	(18.72)	(113.62)
C)	CASH FLOW FROM FINANCING ACTIVITIES		
	Interest Expense	(0.52)	-
	Lease repayment	(0.66)	(0.20)
	Dividend paid	(13.36)	-
	Net Cash from Financing Activities (C)	(14.55)	(0.20)
	Net Increase in Cash & Cash Equivalents (A+B+C)	(5.97)	(34.04)
	Opening Cash & Cash Equivalents	23.54	55.41
	Closing Cash & Cash Equivalents	17.57	21.37



For **VENUS REMEDIES LIMITED**
[Signature]
CHAIRMAN & MANAGING DIRECTOR


Notes to the standalone financial results: -

1. The above Standalone Financial Results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 26th October 2026. The statutory auditors of the company have carried out limited review of the above Standalone Financial Result for the quarter and half year ended 30th September 2026, pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.
2. The Standalone Financial Results are prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India.
3. The company has a wholly owned subsidiary named Venus Pharma GmbH in Germany and step-down subsidiary of Venus Pharma GmbH named as Venus Pharma Kft in Hungary.
4. During the year, the Company reviewed the remaining useful life of its intellectual property (IP) in accordance with Ind AS 38. Consequently, depreciation and amortisation expense for the period is higher by Rs.2.77Cr.
5. The Company's investment in its wholly owned subsidiary, Venus Pharma GmbH, remains pending for formal share allotment, as such allotment is not mandated under the applicable regulations in Germany. The Management considers the investment strategic in nature and, pursuant to the ongoing restructuring of European operations, has engaged a Germany-based financial consultancy firm to advise on the appropriate framework & mechanism.
6. Previous year / period figures have been regrouped/ reclassified wherever necessary.
7. The group has only one reportable segment namely "Pharmaceuticals"

**For and on behalf of Board of Directors
for VENUS REMEDIES LIMITED**



Date: 26-10-2026



Pawan Chaudhary
(Managing Director)
DIN: 00435503

CIN : L21002CH1989PLC009705



J. K. JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

S.C.O. 1136-37, SECTOR 22-B, CHANDIGARH - 160 022

0172-270 4536-37 Fax : 0172-270 4537

E - mail : jkjcaps@rediffmail.com

Independent Auditor's Limited Review Report on Unaudited Quarterly Consolidated financial results of Venus Remedies Limited pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended

To

The Board of Directors

VENUS REMEDIES LIMITED

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **VENUS REMEDIES LIMITED ("the Holding Company")** and its subsidiary (collectively referred to as '**the Group**'), for the Quarter and half year ended 30th September 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following Subsidiary:

- i. Venus Pharma GmbH
- ii. Venus Pharma Kft (Subsidiary of Venus Pharma GmbH)



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the report of referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. **Emphasis of matter**

We draw attention to Note 5 of the accompanying Statement, which describes the outstanding share application money amounting to INR 2,859.72 Lakhs in respect of Venus Pharma GmbH, a wholly owned subsidiary of the Company. The share allotment against this amount has been pending and as per management representation it is not mandatory to allot under the applicable laws of Germany.

Management has represented that they consider this investment strategic in nature and that the parent company intends to recover this amount in due course as a result of the restructuring of European operations carried out by the Management in FY 2026-27. Although the subsidiary is currently facing financial challenges, the Company has reiterated its intention to provide the necessary financial and operational support during the transition period.

Our opinion is not modified in respect of above matters.

7. **Other Matter**

The accompanying statement of quarterly unaudited standalone financial results includes the unaudited interim financial results and other financial information in respect of two subsidiaries, whose financial result and other information without giving the effect to the elimination of the intra group transaction reflect groups as:

Name of Subsidiary	Revenue (INR in Crores)	Net Profit/(Loss) (INR in Crores)	Total comprehensive Income (INR in Crores)
Venus Pharma GmbH	3.64	(5.84)	(5.84)
Venus Pharma Kft	Nil	Nil	Nil



Further, subsidiary is located outside India, whose financial results have been prepared in accordance with accounting principles generally accepted in India, and which have been reviewed by us under standard of auditing applicable in India. Our opinion, in so far as it relates to the balances and affairs of the subsidiary, is based on our audit report.

Our conclusion on the Statement is not modified in respect of the above matter.

For J.K Jain & Associates
Chartered Accountants
FRN-004025N




CA Anurag Verma
Partner
M. No. 555033
UDIN: 26555033YMRCUY7791
Date: 26th October, 2026


CIN : L21002CH1989PLC009705

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2026

(Rs. In Crores except EPS)

S. No.	PARTICULARS						
		QUARTER ENDED ON			HALF YEAR ENDED ON		YEAR ENDED ON
		30/09/2026	30/06/2026	30/09/2025	30/09/2026	30/09/2025	31/03/2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue						
	(a) Revenue from Operations	218.76	178.86	192.75	397.62	329.93	769.60
	(b) Other Income	0.51	2.62	1.71	3.13	5.12	12.58
	Total Income	219.27	181.48	194.46	400.75	335.05	782.18
2	Expenses						
	(a) Cost of Material Consumed	97.39	83.14	106.51	180.53	177.84	387.98
	(b) Purchase of stock in trade	2.14	1.12	1.86	3.26	4.13	10.76
	(c) Changes in Inventories of finished goods, work-in-progress & Stock in Trade	6.73	0.02	(1.06)	6.75	(0.51)	(11.47)
	(d) Employee benefits expense	26.53	23.37	22.97	49.90	43.28	88.68
	(e) Finance Cost	-	-	0.01	-	0.02	0.04
	(f) Depreciation & amortization expense	9.54	6.77	6.17	16.31	12.35	25.67
	(g) Selling, Manufacturing and Administrative expenses	37.49	32.35	27.16	69.84	50.51	128.20
	(h) Research & Development expenses	5.98	4.67	4.35	10.65	8.34	18.17
	Total Expense	185.80	151.44	167.97	337.24	295.96	648.02
3	Profit before taxes (1-2)	33.47	30.04	26.49	63.51	39.09	134.16
4	Exceptional Items	-	-	-	-	-	-
5	Profit after exceptional items (3 + 4)	33.47	30.04	26.49	63.51	39.09	134.16
	EBIDTA (3+2e+2f)	43.01	36.81	32.67	79.82	51.46	159.86
6	Tax Expense						
A	Current Tax	9.26	8.20	6.45	17.46	10.15	32.89
B	Deferred Tax	(1.44)	(1.13)	(0.09)	(2.57)	(0.79)	(1.52)
C	Tax expense related to previous year	-	-	-	-	-	-
7	Net Profit /(Loss) for the period (5 - 6)	25.65	22.97	20.13	48.62	29.73	102.78
8	Other Comprehensive Income						
A	(I) Items that will not be classified to profit & loss	0.03	0.03	(0.12)	0.06	(0.24)	0.11
B	(I) Foreign Currency Translation Reserve	0.02	(0.01)	0.74	0.01	(0.51)	(0.82)
C	(I) Items that will be classified to profit & loss	(0.46)	5.89	0.63	5.43	4.36	0.71
	(II) Income tax relating to items that may be reclassified to Profit & loss	-	-	-	-	-	-
	Total other comprehensive Income Net of Income Tax	(0.41)	5.91	1.26	5.50	3.61	0.01
9	Total comprehensive Income for the period (7+/-8)	25.24	28.88	21.39	54.12	33.34	102.80
10	Paid up equity share capital	13.37	13.37	13.37	13.37	13.37	13.37
	(Face Value of Equity Shares)	10	10	10	10	10	10
11	Other Equity	-	-	-	-	-	650.38
12	Earning per share (of Rs. 10/- each)						
	(a) Basic	19.19	17.18	15.06	36.37	22.24	76.89
	(b) Diluted	19.19	17.18	15.06	36.37	22.24	76.89




For **VENUS REMEDIES LIMITED**

CHAIRMAN & MANAGING DIRECTOR


CIN : L21002CH1989PLC009705

Unaudited Statement of Consolidated Assets and Liabilities

(₹ In Crore)


Particulars	As at 30/09/2026 (Un Audited)	As at 31/03/2026 (Audited)
ASSETS		
Non-Current Assets		
(a) Property, Plant & Equipment	120.45	125.43
(b) Capital work in progress	74.76	51.36
(c) Intangible Assets	85.70	93.98
(d) Right of Use Assets	11.24	12.19
(e) Financial Assets		
(i) Investments	172.37	163.82
(ii) Other Financial Assets	6.43	7.74
(f) Other Non-Current Assets	5.71	3.98
Total Non Current Assets	476.66	458.50
Current Assets		
(a) Inventories	132.14	129.37
(b) Financial Assets		
(i) Investments	68.08	73.80
(ii) Trade Receivables	87.67	103.28
(iii) Cash and Cash Equivalents	18.14	25.12
(iv) Others Bank Balances	3.93	4.49
(v) Other Financial Assets	1.14	0.53
(c) Current Tax Assets	8.23	8.18
(d) Other Current Assets	43.59	50.45
Total Current Assets	362.91	395.20
Total Assets	839.57	853.70
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	13.37	13.37
(b) Other Equity	691.14	650.38
Total equity	704.51	663.75
Liabilities		
Non-Current Liabilities		
(a) Provisions	3.53	2.81
(b) Deferred Tax Liabilities (net)	11.65	14.34
(c) Financial Liabilities		
(i) Lease Liabilities	10.32	11.05
Total Non-Current Liabilities	25.50	28.20
Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade payables		
(A) Total outstanding dues of micro enterprises and small enterprises	13.69	12.41
(B) Total outstanding dues of creditors other than micro and small enterprises	39.55	101.08
(iii) Lease Liabilities	1.42	1.36
(iv) Other Financial Liabilities	50.46	40.51
(b) Other Current Liabilities	2.15	2.08
(c) Provisions	2.29	4.32
Total Current Liabilities	109.56	161.76
Total Equity and Liabilities	839.57	853.70



For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR


UNAUDITED STATEMENT OF CONSOLIDATED CASH FLOW FOR THE PERIOD ENDED 30TH SEPTEMBER 2026

		(₹ in Crore)	
	PARTICULARS	For the Year ended 30/09/2026	For the Year ended 30/09/2025
		Un Audited	Un Audited
A)	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit Before Tax	63.51	39.10
	Adjustment for Depreciation	16.31	12.35
	Adjustment for loss/(profit) on sale of Property plant and Equipment	0.01	0.07
	Interest Expense	0.52	0.02
	Rent Received	(0.23)	(0.21)
	Gain on sale of Mutual Fund	(1.79)	(1.55)
	Interest Received	(0.37)	(1.22)
	Operating Profit before working capital changes	77.96	48.56
	Less Tax Paid	(22.02)	(9.22)
	Adjustments for increase /decrease in Current Assets	0.13	3.65
	Decrease / Increase in Current Liabilities/ Provisions	(30.76)	45.55
	Decrease / Increase in Others Non-Current Assets and Other Financial Assets	(0.41)	(2.73)
	Provision for gratuity,leave encashment and Income Tax	1.37	(4.70)
	Net Cash Flow from operating activities (A)	26.26	81.11
B)	CASH FLOW FROM INVESTING ACTIVITIES		
	Rent Received	0.23	0.21
	Purchase of Property plant and equipment	(25.86)	(12.89)
	Right of Use Assets	-	(0.05)
	Sale of Property plant and equipment	0.33	0.06
	Investment in Mutual funds / Fixed Deposit	4.42	(103.71)
	Gain on sale of Mutual Fund	1.79	1.55
	Interest Received	0.37	1.22
	Net Cash Flow from Investing Activities (B)	(18.72)	(113.61)
C)	CASH FLOW FROM FINANCING ACTIVITIES		
	Proceeds from term Loans (Net)	-	(0.36)
	Interest Expense	(0.52)	(0.02)
	Lease Repayment	(0.66)	(0.20)
	Dividend Paid	(13.36)	-
	Net Cash from Financing Activities (C)	(14.55)	(0.58)
	Net Increase in Cash & Cash Equivalents (A+B+C)	(7.00)	(33.08)
	Unrealised Loss/(gain) on foreign currency cash and cash equivalents	0.02	(2.45)
	Opening Cash & Cash Equivalents	25.12	57.52
	Closing Cash & Cash Equivalents	18.14	21.99




Notes to the consolidated financial results: -

1. The above Consolidated Financial Results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 26th October 2026. The statutory auditors of the holding company have carried out limited review of the above Consolidated Financial Result for the quarter and half year ended 30th September 2026, pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.
2. The Consolidated Financial Results are prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India.
3. The parent company has a wholly owned subsidiary named Venus Pharma GmbH in Germany. Venus Pharma Kft is a step-down subsidiary of the parent company through Venus Pharma GmbH. The consolidated financial results include the results of both Venus Pharma GmbH and its step-down subsidiary Venus Pharma Kft.
4. During the year, the parent company reviewed the remaining useful life of its intellectual property (IP) in accordance with Ind AS 38. Consequently, depreciation and amortisation expense for the period is higher by Rs.2.77Cr.
5. The parent company's investment in its wholly owned subsidiary, Venus Pharma GmbH, remains pending for formal share allotment, as such allotment is not mandated under the applicable regulations in Germany. The Management considers the investment strategic in nature and, pursuant to the ongoing restructuring of European operations, has engaged a Germany-based financial consultancy firm to advise on the appropriate framework & mechanism.
6. Previous year / period figures have been regrouped/ reclassified wherever necessary.
7. The group has only one reportable segment namely "Pharmaceuticals"



Date: 26.10.2026

**For and on behalf of Board of Directors
for VENUS REMEDIES LIMITED**


Pawan Chaudhary
(Managing Director)

DIN: 00435503

CIN : L21002CH1989PLC009705